DE2163055A1 - Lokalanästhetisches Mittel - Google Patents
Lokalanästhetisches MittelInfo
- Publication number
- DE2163055A1 DE2163055A1 DE19712163055 DE2163055A DE2163055A1 DE 2163055 A1 DE2163055 A1 DE 2163055A1 DE 19712163055 DE19712163055 DE 19712163055 DE 2163055 A DE2163055 A DE 2163055A DE 2163055 A1 DE2163055 A1 DE 2163055A1
- Authority
- DE
- Germany
- Prior art keywords
- tetrodotoxin
- local anesthetic
- lidocaine
- duration
- anesthetic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003589 local anesthetic agent Substances 0.000 title claims description 45
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 claims description 62
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 claims description 62
- 229950010357 tetrodotoxin Drugs 0.000 claims description 61
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 38
- 229960004194 lidocaine Drugs 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 17
- 230000003444 anaesthetic effect Effects 0.000 claims description 14
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- COVOMQKTVSVWBZ-CJCGOCGYSA-N deoxytetrodotoxin Chemical compound O1C(C2(O)CO)(O)OC3C(O)C1[C@@H]1CN=C(N)NC12C3O COVOMQKTVSVWBZ-CJCGOCGYSA-N 0.000 claims description 8
- 229960004919 procaine Drugs 0.000 claims description 8
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 8
- 229960003920 cocaine Drugs 0.000 claims description 7
- 229960002023 chloroprocaine Drugs 0.000 claims description 6
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 6
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 6
- 229950007049 phenacaine Drugs 0.000 claims description 6
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 claims description 6
- 229960001807 prilocaine Drugs 0.000 claims description 6
- 229960002372 tetracaine Drugs 0.000 claims description 6
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 6
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 5
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 claims description 5
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 claims description 5
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims description 5
- 229960003150 bupivacaine Drugs 0.000 claims description 5
- 229960003369 butacaine Drugs 0.000 claims description 5
- 229960005388 hexylcaine Drugs 0.000 claims description 5
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 5
- 229960003981 proparacaine Drugs 0.000 claims description 5
- 229960001747 cinchocaine Drugs 0.000 claims description 4
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 claims description 3
- 229950003255 propoxycaine Drugs 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical class NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960000385 dyclonine Drugs 0.000 claims description 2
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical class NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001896 pramocaine Drugs 0.000 claims description 2
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 claims description 2
- -1 Cyclomethy ^ cain Chemical compound 0.000 claims 2
- 229960003502 oxybuprocaine Drugs 0.000 claims 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 14
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 12
- 229930182837 (R)-adrenaline Natural products 0.000 description 11
- 229960005139 epinephrine Drugs 0.000 description 11
- 229960005015 local anesthetics Drugs 0.000 description 11
- 210000003497 sciatic nerve Anatomy 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 230000036407 pain Effects 0.000 description 6
- 210000004706 scrotum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical group O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229940072358 xylocaine Drugs 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 3
- 229960004741 cyclomethycaine Drugs 0.000 description 3
- 238000002692 epidural anesthesia Methods 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- HYKGUEIYMKVUSR-NPULLEENSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C HYKGUEIYMKVUSR-NPULLEENSA-N 0.000 description 1
- LFXVBFTVUBWIQT-UHFFFAOYSA-N 3,4,4a,5,6,7,8,8a-octahydro-2h-quinazolin-1-amine Chemical compound C1CCCC2N(N)CNCC21 LFXVBFTVUBWIQT-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101000874088 Centruroides noxius Toxin Cn3 Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101000761023 Loxosceles intermedia U2-sicaritoxin-Li1a Proteins 0.000 description 1
- 101000675481 Naja sputatrix Neurotoxin 3 Proteins 0.000 description 1
- 101000723129 Oxyuranus scutellatus scutellatus Short neurotoxin 1 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000269387 Taricha Species 0.000 description 1
- 241001505535 Taricha torosa Species 0.000 description 1
- 241001441729 Tetraodontoidei Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001432 effect on motor function Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10994271A | 1971-01-26 | 1971-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2163055A1 true DE2163055A1 (de) | 1972-10-12 |
Family
ID=22330411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712163055 Pending DE2163055A1 (de) | 1971-01-26 | 1971-12-18 | Lokalanästhetisches Mittel |
| DE2163054A Expired DE2163054C3 (de) | 1971-01-26 | 1971-12-18 | Lokalanästhetisches Mittel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2163054A Expired DE2163054C3 (de) | 1971-01-26 | 1971-12-18 | Lokalanästhetisches Mittel |
Country Status (18)
| Country | Link |
|---|---|
| AT (2) | AT310939B (enExample) |
| AU (1) | AU465875B2 (enExample) |
| BE (2) | BE776769A (enExample) |
| BR (2) | BR7108429D0 (enExample) |
| CA (2) | CA983850A (enExample) |
| DD (2) | DD96144A5 (enExample) |
| DE (2) | DE2163055A1 (enExample) |
| DK (2) | DK130389B (enExample) |
| ES (2) | ES398108A1 (enExample) |
| FR (2) | FR2123277B1 (enExample) |
| GB (1) | GB1370904A (enExample) |
| HU (2) | HU162347B (enExample) |
| IE (2) | IE35937B1 (enExample) |
| LU (1) | LU64664A1 (enExample) |
| NL (2) | NL7117404A (enExample) |
| NO (2) | NO135891C (enExample) |
| SE (2) | SE391127B (enExample) |
| ZA (2) | ZA718326B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998043619A3 (en) * | 1997-04-02 | 1998-12-30 | Univ California | Method of local anesthesia |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917894A (en) * | 1988-06-29 | 1990-04-17 | Beecham Inc. | Rapid-onset long-duration oral anesthetic composition |
| US6326020B1 (en) | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
| RU2277097C1 (ru) * | 2004-12-27 | 2006-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Высокомеченный тритием дигидрохлорид [3h]сакситоксина |
| ES2691411T3 (es) | 2006-03-27 | 2018-11-27 | Wex Medical Limited | Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia |
| US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
| PL2968225T3 (pl) | 2013-03-15 | 2019-08-30 | The Children's Medical Center Corporation | Preparaty skojarzone neosaksytoksyny do przedłużonego znieczulenia miejscowego |
-
1971
- 1971-12-07 SE SE7115655A patent/SE391127B/xx unknown
- 1971-12-07 SE SE7115654A patent/SE391286B/xx unknown
- 1971-12-10 NO NO4557/71A patent/NO135891C/no unknown
- 1971-12-10 NO NO4558/71A patent/NO135892C/no unknown
- 1971-12-13 ZA ZA718326A patent/ZA718326B/xx unknown
- 1971-12-13 ZA ZA718327A patent/ZA718327B/xx unknown
- 1971-12-14 DK DK609571AA patent/DK130389B/da unknown
- 1971-12-16 BE BE776769A patent/BE776769A/xx unknown
- 1971-12-16 BE BE776768A patent/BE776768A/xx unknown
- 1971-12-16 HU HUAA688A patent/HU162347B/hu unknown
- 1971-12-16 HU HU71AA689A patent/HU162185B/hu unknown
- 1971-12-17 DD DD159910A patent/DD96144A5/xx unknown
- 1971-12-17 DD DD159688A patent/DD96400A5/xx unknown
- 1971-12-17 CA CA130,377A patent/CA983850A/en not_active Expired
- 1971-12-17 NL NL7117404A patent/NL7117404A/xx not_active Application Discontinuation
- 1971-12-17 GB GB5865871A patent/GB1370904A/en not_active Expired
- 1971-12-17 AT AT1084971A patent/AT310939B/de not_active IP Right Cessation
- 1971-12-17 NL NL7117401A patent/NL7117401A/xx unknown
- 1971-12-17 CA CA130,378A patent/CA986012A/en not_active Expired
- 1971-12-17 AT AT1084871A patent/AT310938B/de not_active IP Right Cessation
- 1971-12-17 DK DK619971A patent/DK131606C/da active
- 1971-12-17 FR FR7145542A patent/FR2123277B1/fr not_active Expired
- 1971-12-17 FR FR7145543A patent/FR2123278B1/fr not_active Expired
- 1971-12-18 DE DE19712163055 patent/DE2163055A1/de active Pending
- 1971-12-18 ES ES398108A patent/ES398108A1/es not_active Expired
- 1971-12-18 DE DE2163054A patent/DE2163054C3/de not_active Expired
- 1971-12-18 ES ES398109A patent/ES398109A1/es not_active Expired
- 1971-12-20 IE IE1611/71A patent/IE35937B1/xx unknown
- 1971-12-20 IE IE1610/71A patent/IE35910B1/xx unknown
- 1971-12-20 BR BR8429/71A patent/BR7108429D0/pt unknown
- 1971-12-20 BR BR8428/71A patent/BR7108428D0/pt unknown
- 1971-12-20 AU AU37100/71A patent/AU465875B2/en not_active Expired
-
1972
- 1972-01-26 LU LU64664D patent/LU64664A1/xx unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998043619A3 (en) * | 1997-04-02 | 1998-12-30 | Univ California | Method of local anesthesia |
| US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3218761C2 (enExample) | ||
| DE69329576T2 (de) | Präzipitation einer oder mehrerer aktiver verbindungen in situ | |
| DE3886075T2 (de) | Verwendung von Metformin zur Herstellung von Arzneimitteln. | |
| DE2163055A1 (de) | Lokalanästhetisches Mittel | |
| DE3937340A1 (de) | Verfahren zur erzeugung von analgesie bei saeugern | |
| DE3130912A1 (de) | Analgetische arzneimittelkombination | |
| DE2427732A1 (de) | Mittel zum anaesthesieren von saeugetieren | |
| DE69430427T2 (de) | Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade | |
| DD265328A5 (de) | Verfahren zur herstellung eines antihypertensiven kombinatspraeparates | |
| DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
| DE3125512A1 (de) | L-arginin-d,l-pyroglutamat als auf neuroedokrinem gebiet wirksames mittel | |
| DE69233432T2 (de) | Verbesserte zusammensetzungen für die euthanasie | |
| DE2753394A1 (de) | Wirkstoffkombination zur selektiven steuerung von immunreaktionen | |
| DE2611979C3 (de) | Mittel zur Behandlung von Blähungen und Durchfall bei Tieren | |
| DE68901931T2 (de) | Zusammensetzungen zur behandlung von gehirn-tumoren. | |
| DE69118685T3 (de) | Zusammensetzungen für euthanasie | |
| DE2432393B2 (de) | Arzneipräparat zur Behandlung von bösartigen Neubildungen | |
| DE2312134C2 (de) | Anthelmintikum | |
| DE2649914A1 (de) | Mittel zum foerdern der fortpflanzungsfaehigkeit von haustieren | |
| DE2228187A1 (de) | Arzneimittel | |
| DE2844534C2 (enExample) | ||
| DE69819875T2 (de) | Anhydrovinblastin zur Behandlung von Krebs | |
| Abdel-Aziz et al. | The action and interaction of diphenhydramine (Benadryl) hydrochloride at the neuromuscular junction | |
| DE3030314A1 (de) | Arzneimittel auf sulfonamidbasis | |
| DE1923772C3 (de) | Oral oder parenteral verabreichbare Arzneimittel mit ulkushemmender Wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHW | Rejection |